Cytotoxic T lymphocytes
Sniping cancer stem cells

Yoshihiko Hirohashi,* Toshihiko Torigoe, Satoko Inoda, Rena Morita, Vitaly Kochin and Noriyuki Sato

Department of Pathology; Sapporo Medical University School of Medicine; Sapporo, Japan

Keywords: cancer stem cell, immunotherapy, tumor antigen, CTL, antigenic peptide

Abbreviations: CSC, cancer stem-like cell; CIC, cancer-initiating cell; CTL, cytotoxic T lymphocyte; TAA, tumor-associated antigen

Cancer stem-like cells (CSCs)/cancer-initiating cells (CICs) are characterized as a small population of cancer cells that have high tumor-initiating ability. CSCs/CICs are resistant to several cancer therapies, and eradication of CSCs/CICs is essential to cure cancer. How can we eradicate CSCs/CICs? Cytotoxic T lymphocytes (CTLs) might be a promising answer.

Cancer stem-like cells (CSCs)/cancer-initiating cells (CICs) are defined as a small population of cancer cells that have (1) high tumor-initiating ability, (2) self-renewal ability and (3) differentiation ability. Therefore, cancer immunotherapy trials using TAAs have recently been performed in several facilities and significant results have been obtained. However, it is still not clear whether the immune system can recognize therapy-resistant CSCs/CICs or not. Some reports on immunity and CSCs/CICs have recently been published, and natural killer (NK) cells and γδT cells have been shown to recognize CSCs/CICs derived from human colon cancer and gliomas; however, CTLs, which are a major component of the acquired immune system, have not been characterized yet.

We analyzed the relation between CTLs and CSCs/CICs. We isolated CSCs/CICs from human colon cancer cells using a side population (SP) technique. Since CTLs recognize antigenic peptides derived from TAAs, we evaluated the expression of TAAs in colon CSCs/CICs and non-CSCs/CICs. Colon CSCs/CICs expressed CEP55, one of the TAAs, at the same level in vitro. Furthermore, CTL clone #41 inhibited the tumor-initiating ability of colon CSCs/CICs in vivo. These findings clearly indicate that treatment-resistant colon CSCs/CICs, as well as non-CSCs/CICs are sensitive to CTLs. Therefore, CTL-based immunotherapy is a promising approach to target CSCs/CICs.

In the next stage, another question has emerged. Which are the best TAAs for CSC/CIC-targeting cancer immunotherapy: (1) CSC/CIC antigens, (2) shared antigens or (3) non-CSC/CIC antigens? Non-CSC/CIC antigens do not seem to be suitable for targeting CSCs/CICs since they are not expressed in CSCs/CICs. Further analyses are under way to address these questions, and we have found that targeting CSC/CIC antigens was more effective than targeting shared antigens in a CTL adoptive transfer model and a DNA vaccination model (unpublished data). Both CSC/CIC antigens and shared antigens are expressed in CSCs/CICs; however, the anti-tumor effects are
different. We are not sure about the exact mechanisms and we are now analyzing; however, these data indicate that targeting CSC/CIC specific antigens is more effective than targeting shared antigens.

The numbers of CTL clones are very restricted and limited in vivo, and the maximum numbers of one CTL clone might be about $10^7$ to $10^8$ cells in the whole body. On the other hand, cancer tissues contain $5 \times 10^8$ cancer cells per gram, and advanced cancer tissues may therefore contain more than $10^{10}$ cancer cells. It is easy to imagine the difficulty in eliminating all cancer cells with such a limited number of CTLs (Estimated effector/target ratio is about 0.001 in the case of $10^7$ CTL and $10^{10}$ cancer cells.). On the other hand, if we focus on just CSCs/CICs targeting CSC/CIC antigens, the situation will be improved (Estimated

![Figure 1. CSC/CIC targeting immunotherapy. (A) Characters of CSC/CIC. CSC/CIC has three distinct characteristics: (1) high tumor-initiating ability, (2) self-renewal ability and (3) differentiation ability. (B) Three groups of tumor-associated antigens. Tumor-associated antigens can be classified into 3 groups according to the expression in CSC/CIC and non-CSC/CIC: (1) CSC/CIC antigens, which are expressed in CSCs/CICs but not in non-CSCs/CICs (e.g., MAGE-A3 and MAGE-A4); (2) shared antigens, which are expressed in both CSCs/CICs and non-CSCs/CICs (e.g., CEP55, SURVIVIN); and (3) non-CSC/CIC antigens, which are expressed in only non-CSCs/CICs but not in CSCs/CICs (e.g., AMACR, HIFPH3). (C) CSC/CIC-targeting immunotherapy. CSC/CIC antigen specific CTLs recognize only higher tumorigenic CSCs/CICs, whereas shared antigen specific CTLs, NK cells and γδT cells recognize both CSCs/CICs and non-CSCs/CICs. CSCs/CICs might be eliminated most efficiently by CSC/CIC antigen-specific CTLs.](image)
effector/target ratio is about 0.1 in the case of $10^7$ CTL, $10^{10}$ cancer cells and 1% frequency of CSCs/CICs). Therefore, targeting CSC/CIC antigens might be a more effective approach to eradicate higher tumorigenic CSCs/CICs and may bring about greater anti-tumor effects (Fig. 1C).

As stated above, NK cells and γδT cells have been reported to recognize CSSs/CICs. However, these immune cells belong to the innate immune system and do not recognize target cells in an antigen-specific manner. Thus, activation of these cells in vivo may not be more effective than CSC/CIC antigen-specific CTLs (Fig. 1C). CTL adoptive transfer therapy has recently been described in detail, and huge numbers of CTLs can be obtained by in vitro culture. Therefore, (2) shared antigens may also be suitable candidates for CTL adoptive transfer therapy using high numbers of CTLs.

In summary, CTLs can recognize CSCs/CICs as well as non-CSCs/CICs, and targeting CSC/CIC antigens with CTLs may be a reasonable approach for CSC/CIC targeting therapy.

References

1. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414:105-11; PMID:11689955; http://dx.doi.org/10.1038/35102167
2. Park CY, Tseng D, Weissman IL. Cancer stem cell-directed therapies: recent data from the laboratory and clinic. Mol Ther 2009; 17:219-30; PMID:19066601; http://dx.doi.org/10.1038/m.008.254
3. van der Bruggen P, Traversari C, Chomez P, Lanquin C, De Plaen E, Van den Eynde B, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254:1643-7; PMID:1840703; http://dx.doi.org/10.1126/science.1840703
4. Hirohashi Y, Torigoe T, Inoda S, Kobayasi J, Nakatsuigawa M, Mori T, et al. The functioning antigens: beyond just as the immunological targets. Cancer Sci 2009; 100:798-806; PMID:19445013; http://dx.doi.org/10.1111/j.1349-7006.2009.01137.x
5. Hirohashi Y, Torigoe T, Inoda S, Takahashi A, Morita R, Nishizawa S, et al. Immune response against tumor antigens expressed on human cancer stem-like cells/tumor-initiating cells. Immunotherapy 2010; 2:201-11; PMID:20635928; http://dx.doi.org/10.2217/imt.10.10
6. Inoda S, Hirohashi Y, Torigoe T, Morita R, Takahashi A, Asanuma H, et al. Cytotoxic T lymphocytes efficiently recognize human colon cancer stem-like cells. Am J Pathol 2011; 178:1805-13; PMID:21435460; http://dx.doi.org/10.1016/j.ajpath.2011.01.004
7. Inoda S, Hirohashi Y, Torigoe T, Nakatsuigawa M, Kiriya K, Nakazawa E, et al. Cep55/c10orf3, a tumor antigen derived from a centrosome residing protein in breast carcinoma. J Immunother 2009; 32:474-85; PMID:19609239; http://dx.doi.org/10.1097/CJI.0b013e3181a1d109
8. Inoda S, Morita R, Hirohashi Y, Torigoe T, Asanuma H, Nakazawa E, et al. The feasibility of Cep55/c10orf3 derived peptide vaccine therapy for colorectal carcinoma. Exp Mol Pathol 2011; 90:55-60; PMID:20950610; http://dx.doi.org/10.1016/j.yexmp.2010.10.001
9. Laird AK. Cell fractionation of normal and malignant tissues. Exp Cell Res 1954; 6:30-44; PMID:13141981; http://dx.doi.org/10.1016/0014-4827(54)90145-7
10. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008; 8:299-308; PMID:18354418; http://dx.doi.org/10.1038/nrc2355